This decision could have life-threatening consequences.

Ghassan has type 2 diabetes. He managed it with a strict treatment routine for over 15 years. However, when he and his family left Gaza in September 2023, to seek safety in Europe, he faced many challenges during the dangerous journey ...

Anis and his family had to flee Syria after they lost everything in the war. The journey was hard, especially since they had their newborn baby with them, and Anis was diagnosed with diabetes while on the move. Anis’s challenging ...

Amina was dealing with an abusive and violent husband while coping with one of her sons' diabetes. Fearing for her children’s lives, she decided to flee. Reaching Europe safely, along with securing her son’s critical insulin supply ...

TB champions, associations and civil society have been playing a pivotal role in pushing back against patent monopolies and high prices that, for more than a decade, have kept newer and safer TB drugs out of the hands of people who ...

Activists present ‘Time for $5’ petition signed by over 206,000 people asking US corporations Cepheid and Danaher to drop test prices

80% of people with diabetes live in low- and middle-income countries, where access to insulin pens is extremely limited due primarily to high prices

In this story, we hear from a person living with diabetes who has made a difficult journey while trying to manage their diabetes treatment.

In this story, we hear from a person living with diabetes who has made a difficult journey while trying to manage their diabetes treatment.

In this story, we hear from a person living with diabetes who has made a difficult journey while trying to manage their diabetes treatment.

In a series of three stories, we hear from people living with diabetes who have made difficult journeys while trying to manage diabetes treatment.

US test maker Cepheid and parent corporation Danaher have ignored global calls for price reductions and have broken their promise from one year ago to be transparent about what it costs to make their medical tests

MSF, WHO, national TB programs, and civil society discussed results in the report, TACTIC: Test, Avoid, Cure TB in Children

MSF report shows many countries lag behind in aligning national paediatric TB policies with WHO guidelines

All insulin manufacturers must price insulin pens at a dollar each in low- and middle-income countries

AMR remains a leading cause of death worldwide nearly a decade after UN member states agreed to make it a priority

Pharmaceutical corporations sell newer diabetes drugs at up to 40,000% markup, while half of people with type 2 diabetes who need insulin* don’t have access.

MSF responds to WHO recommendation of three new regimens of shorter, all-oral TB regimens, outlines the importance of affordable access to these regimens.

MSF responds to WHO declaring mpox a PHEIC, outlines need for all components of an outbreak response and offers concrete actions to improve access and use of existing vaccines.

There were an estimated 1.3 million new HIV infections in 2023, but ViiV distributed only enough CAB-LA for approximately 13,000 people in 2023